Hemispherx is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders

Hemispherx is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders

Latest From Hemispherx

August 15th, 2019|

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to [...]

  • Hemispherx News 04

Prostate Cancer News Today Provides an Ampligen Upate

July 9th, 2019|

Prostate Cancer News Today Provides an Ampligen Update We recently announced that the Roswell Park Comprehensive Cancer Center had received FDA authorization to proceed with its Phase 2 study using our lead [...]

Latest From Hemispherx

August 15th, 2019|

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to [...]

  • Hemispherx News 04

Prostate Cancer News Today Provides an Ampligen Upate

July 9th, 2019|

Prostate Cancer News Today Provides an Ampligen Update We recently announced that the Roswell Park Comprehensive Cancer Center had received FDA authorization to proceed with its Phase 2 study using our lead [...]

Want More Info?

Click below for all our contact information